Breast cancer vaccine - Quantum Immunologics

Drug Profile

Breast cancer vaccine - Quantum Immunologics

Alternative Names: OFA/iLRP-loaded autologous monocyte-derived dendritic cells

Latest Information Update: 24 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of South Alabama
  • Developer Quantum Immunologics; University of South Alabama
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Breast cancer

Most Recent Events

  • 24 Sep 2015 No development reported - Phase-I/II for Breast cancer (Metastatic disease, Second-line therapy or greater) in USA (Intradermal)
  • 01 May 2008 Phase-I/II clinical trials in Breast cancer in USA (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top